Breaking Down Revenue Trends: Telix Pharmaceuticals Limited vs Supernus Pharmaceuticals, Inc.

Pharma Revenue Growth: Supernus vs. Telix

__timestampSupernus Pharmaceuticals, Inc.Telix Pharmaceuticals Limited
Wednesday, January 1, 201412204500028336824
Thursday, January 1, 201514442700032319194
Friday, January 1, 201621500300029404631
Sunday, January 1, 201730223800031769230
Monday, January 1, 201840889700020439380
Tuesday, January 1, 201939275500024186536
Wednesday, January 1, 20205203970004680000
Friday, January 1, 20215797750004898000
Saturday, January 1, 2022667238000155984000
Sunday, January 1, 2023607521000496659000
Loading chart...

Infusing magic into the data realm

Revenue Trends in Pharmaceuticals: A Comparative Analysis

In the dynamic world of pharmaceuticals, revenue growth is a key indicator of a company's market position and innovation prowess. Over the past decade, Supernus Pharmaceuticals, Inc. has demonstrated a robust revenue trajectory, with an impressive 450% increase from 2014 to 2023. This growth underscores their strategic advancements and market penetration. In contrast, Telix Pharmaceuticals Limited, while starting from a lower base, has shown a remarkable surge, particularly in recent years, with a staggering 1,650% increase in revenue from 2020 to 2023. This leap highlights Telix's successful product launches and expanding market reach. The data reveals a compelling narrative of two companies navigating the competitive landscape with distinct strategies, offering valuable insights into the evolving pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025